BCM
NAGE icon

Bridgeway Capital Management’s Niagen Bioscience NAGE Stock Holding History

Bridgeway Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-67,179
Closed -$427K – 1330
2025
Q4 		$427K Sell
67,179
-25,000
-27% -$174K 0.01% 853
2025
Q3 		$860K Hold
92,179
– – 0.02% 721
2025
Q2 		$1.33M Buy
+92,179
New +$910K 0.03% 611

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bridgeway Capital Management's NAGE Position: Q1 2026 in Review

Bridgeway Capital Management sold out of Niagen Bioscience (NAGE) in Q1 2026, closing a stake of 67,179 shares — an estimated $427K sold.

Bridgeway Capital Management first reported a position in NAGE in Q2 2025 and held it in 3 quarters. The position peaked at $1.33M in Q2 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Bridgeway Capital Management reported no remaining Niagen Bioscience position as of Q1 2026 after selling out during the quarter.
  • Bridgeway Capital Management sold 67,179 Niagen Bioscience shares in Q1 2026, an estimated $427K.
  • Bridgeway Capital Management first reported a position in Niagen Bioscience in Q2 2025 and held it in 3 quarters.
  • Bridgeway Capital Management's Niagen Bioscience position peaked at $1.33M in Q2 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.